Tuberculosis in the COVID-19 pandemic period. (Bibliography review)
DOI:
https://doi.org/10.52692/1857-0011.2021.3-71.31Keywords:
tuberculosis, COVID-19, diagnosisAbstract
As a result of the analysis of bibliographic sources, important information was elucidated regarding the clinical manifestations and management of patients with tuberculosis associated with COVID-19 infection. The similarity of the clinical manifestations of these two diseases was confirmed along with the importance of investigations by the presence of “ground glass” opacities for the diagnosis of COVID-19 infection. The increased mortality among patients suffering from co-infection TB/COVID-19 was argued by the presence of cardiovascular and endocrine comorbidities.References
Wang Y, Xu J, Wang Y, Hou H, Shi L, Yang H. Prevalence of comorbid tuberculosis amongst COVID- 19 patients: A rapid review and meta- analysis Int J Clin Pract. 2021;75:e14867.
Wang Y, Feng R, Xu J, Hou H, Feng H, Yang H. An updated metaanalysis on the association between tuberculosis and COVID-19 severity and mortality. J Med Virol. 2021;93(10):5682-5686.doi:10.1002/jmv.27119.
Tian J, Yan S, Wang H, et al. Hanshiyi formula, a medicine for Sars-CoV2 infection in China, reduced the proportion of mild and moderate COVID-19 patients turning to severe status: a cohort study. Pharmacol Res. 2020;161:105127
Du RH, Liang LR, Yang CQ, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Res J. 2020;55(5)
Hu Y, Wang T, Hu Z, et al. Clinical efficacy of glucocorticoid on the treatment of patients with COVID-19 pneumonia: a single-center experience. Biomed Pharmacother. 2020;130:110529
Mo P, Xing Y, Xiao Y, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis. 2020.
World Health Organization. Global tuberculosis report 2021. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO. https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131en.pdf. Date last accessed: September 19. 202
Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; 382(18):1708-1720. doi: 10.1056/NEJMoa2002032.
Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARSCov-2) outside of Wuhan, China: retrospective case series. BMJ 2020;368:m606. doi: 10.1136/bmj.m606.
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020: 395(10229): 1054-1062.
Ong CWM, Migliori GB, Raviglione M, et al. Epidemic and pandemic viral infections:impact on tuberculosis and the lung. A consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN) and members of ESCMID Study Group for Mycobacterial Infections (ESGMYC). Eur Respir J 2020: 56(4):2001727. doi: 10.1183/13993003.01727-2020.
Migliori GB, Thong PM, Akkerman O, et al. Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January-April 2020. Emerg Infect Dis.2020;26(11):2709-2712.
McQuaid C F, Vassall A, Cohen T, et al. The impact of COVID-19 on TB: a review of the data. Int J Tuberc Lung Dis 2021; 25(6):436-446.
McQuaid CF, McCreesh N, Read JM, et al. The potential impact of COVID-19-related disruption on tuberculosis burden. Eur Respir J. 2020 Aug 13;56(2):2001718.
Migliori GB, Thong PM, Alffenaar JW, et al. Gauging the impact of the COVID-19pandemic on tuberculosis services: a global study. Eur Respir J. 2021:2101786. doi:10.1183/13993003.01786-2021
Motta I, Centis R, D’Ambrosio L, et al. Tuberculosis, COVID-19 and migrants: Preliminary analysis of deaths occurring in 69 patients from two cohorts. Pulmonology. 2020;26(4):233-240.
Visca D, Ong CWM, Tiberi S, et al. Tuberculosis and COVID-19 interaction: A review of biological, clinical and public health effects. Pulmonology 2021; 27(2):151-165.
Tadolini M, Codecasa LR, García-García J-M, et al. Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. Eur Respir J 2020; 56: 2001398.
Migliori GB, Visca D, van den Boom M; contributing members of the Global Tuberculosis Network. Tuberculosis, COVID-19 and hospital admission: Consensus on pros and cons based on a review of the evidence. Pulmonology. 2021;27(3):248-256
Wen Z, Chi Y, Zhang L, et al. Coronavirus Disease 2019:Initial Detection on Chest CT in a Retrospective Multicenter Study of 103 Chinese Patients. Radiol Cardiothorac Imaging. 2020;2(2):e200092.
Duarte R, Aguiar A, Pinto M, et al. Different disease,same challenges: Social determinants of tuberculosis and COVID-Pulmonology. 2021;27(4):338-344. doi:10.1016/j.pulmoe.2021.02.002.
Alves A, Aguiar A, Migliori GB, Duarte R. COVID-19 related hospital re-organization and trends in tuberculosis diagnosis and admissions: reflections from Portugal. Arch Bronconeumol (Engl Ed). 2021 Sep 25. doi: 10.1016/j.arbres.2021.09.005.
Visca D, Centis R, D’Ambrosio L, et al. The need for pulmonary rehabilitation following tuberculosis treatment. Int J Tuberc Lung Dis 2020; 24: 720–722.
Visca D, Zampogna E, Sotgiu G, et al. Pulmonary rehabilitation is effective in patients with tuberculosis pulmonary sequelae. Eur Respir J 2019;53(3):1802184.
Allwood BW, van der Zalm MM, Amaral AFS, et al. Post-tuberculosis lung health:perspectives from the First International Symposium. Int J Tuberc Lung Dis 2020; 24: 820–828.
Muñoz-Torrico M, Cid-Juárez S, Gochicoa-Rangel L, et al. Functional impact of sequelae in drug-susceptible and multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2020 Jul 1;24(7):700-705.Muñoz-Torrico M, Cid-Juárez S, Gochicoa-Rangel L, et al. Functional impact of sequelae in drug-susceptible and multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2020 Jul1;24(7):700-705.
Muñoz-Torrico M, Rendon A, Centis R, et al. Is there a rationale for pulmonary rehabilitation following successful chemotherapy for tuberculosis? J Bras Pneumol 2016; 42(5): 374-385
Migliori GB Marx FM, Ambrosino N.et al. Clinical standards for the assessment, management, and rehabilitation of post-TB lung disease. Int J Tuberc Lung Dis.2021;25(10):797- 813. doi: 10.5588/ijtld.21.0425.
Zampogna E, Paneroni M, Belli S, et al. Pulmonary Rehabilitation in Patients Recovering from COVID-19. Respiration. 2021;100(5):416-422. doi: 10.1159/000514387
Visca D, Migliori GB, Dinh-Xuan AT, et al. The Role of Blood Gas Analysis in the Post-Acute Phase of COVID-19 Pneumonia. Arch Bronconeumol. 2021 Jun 17. doi: 10.1016/j.arbres.2021.06.003.
Zampogna E, Ambrosino N, Migliori GB, et al. Time course of exercise capacity in patients recovering from COVID-19-associated pneumonia. Authors’ reply. J Bras Pneumol.2021;47(4):e20210328. English, Portuguese. doi: 10.36416/1806-3756/e20210328
Singh S. Post-COVID rehabilitation. In: Fabre A, Hurst J, Ramjug S Eds. Monograph, ERS (2021) figshare. Preprint. https://doi.org/10.6084/m9.figshare.14096275.v1.
Gramegna A, Mantero M, Amati F, et al. Post-COVID sequelae. In: Fabre A, Hurst J, Ramjug S Eds. Monograph, ERS (2021) figshare. Preprint. https://doi.org/10.6084/m9.figshare.14096263.v1.
Glaziou P. Predicted impact of the COVID-19 pandemic on global tuberculosis deaths in 2020.medRxiv 2020.04.28.20079582; doi: https://doi.org/10.1101/2020.04.28.20079582
Hogan AB, Jewell BL, Sherrard-Smith E, et al. Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study. Lancet Glob Health. 2020; 8(9): e1132–e1141
Cilloni L, Fu H, Vesga JF, et al. The potential impact of the COVID-19 pandemic on the tuberculosis epidemic a modelling analysis. EClinicalMedicine. 2020 Oct 24;28:100603
Protocol clinic naţional „Tuberculoza la adult”, Chişinău, 2020
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Bulletin of the Academy of Sciences of Moldova. Medical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
